Rebecca J Calthorpe

Developing a Core Outcome Set for cystic fibrosis (CF): a systematic review of outcomes used in CF research

Bethinn Evans, Rebecca J Calthorpe, Alex Yule, Carmel Hughes et autres

gb, au (code pays fourni par la source)

Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis

Rebecca J Calthorpe, Sherie J. Smith, Nikki Jahnke, Alan Robert Smyth

RATIONALE: Improved understanding and treatment of cystic fibrosis (CF) has led to longer life expectancy, which is accompanied by an increasingly complex regimen of treatments. Suboptimal adherence to the treatment plan, in the context of respiratory disease, is associated with poorer health …

gb (code pays fourni par la source)

P109 Development of a universal core outcome set for cystic fibrosis (COS-CF): protocol and systematic review

Bethinn Evans, Rebecca J Calthorpe, A.R. Smyth, Damian G. Downey et autres

gb (code pays fourni par la source)

EPS4.05CF Tummy Tracker: development of a cystic fibrosis-specific patient reported outcome measure for daily gastrointestinal symptom burden

Rebecca J Calthorpe, Hishaam Saumtally, Laura Howells, N. Goodchild et autres

gb, ca, ch (code pays fourni par la source)

Exploring the outcomes and endpoints used in gastrointestinal research in cystic fibrosis: a systematic review

Rebecca J Calthorpe, Alexander Yule, J. Holaman, Sherie J. Smith et autres

Abstract Background Cystic fibrosis (CF) research has increasingly focused on understanding the extra-pulmonary manifestations of CF, including on the gastrointestinal (GI) system. The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies outside the lungs is also a topic of research …

gb, au (code pays fourni par la source)

CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden

Rebecca J Calthorpe, Hisham A. Saumtally, Laura Howells, N. Goodchild et autres

Objective: To develop a cystic fibrosis (CF)-specific patient-reported outcome measure (PROM) to measure the daily burden of gastrointestinal symptoms for people with cystic fibrosis (pwCF) aged 12 years and older and address the lack of validated outcome measures for gastrointestinal symptoms in …

gb, ch (code pays fourni par la source)

639 CF Tummy Tracker: adherence to a daily patient-reported outcome measure to track gastrointestinal burden in cystic fibrosis

Hishaam Saumtally, Rebecca J Calthorpe, N. Goodchild, Kerry-Lee Watson et autres

P280 Rapid review of the outcome measures and endpoints used to measure gastrointestinal disease in cystic fibrosis (CARDS-CF study)

A. Yule, J. Holaman, Hugh Barr, Rebecca J Calthorpe et autres

gb (code pays fourni par la source)

P278 CF Tummy Tracker: ACF-specific patient reported outcome measure for daily gastrointestinal symptom burden

Rebecca J Calthorpe, Hishaam Saumtally, Laura Howells, N. Goodchild et autres

gb (code pays fourni par la source)

Caffeine Promotes Epithelial Wound Healing Through a TGFβ-dependent Pathway

Elizabeth D. Cash, Rebecca J Calthorpe, Chitra Joseph, Amanda T. Goodwin et autres

gb (code pays fourni par la source)

Peer Review Report For: A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era [version 2; peer review: 2 approved, 3 approved with reservations]

Rebecca J Calthorpe, Natalie Goodchild, Vigilius Gleetus, Vinishaa Premakumar et autres

Background Gastrointestinal symptoms in cystic fibrosis (CF) are common and intrusive to daily life. Relieving gastrointestinal symptoms was identified as an important research priority and previously explored in an international survey in 2018. However, following the widespread introduction of cystic fibrosis transmembrane …

gb, it, us (code pays fourni par la source)

Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries

Rebecca J Calthorpe, Margaret Rosenfeld, Christopher Hooper Goss, Nicole Green et autres

BACKGROUND: Relieving gastrointestinal symptoms is a research priority in cystic fibrosis. Emerging evidence highlights effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on gastrointestinal function, including pancreatic sufficiency. This study explores ivacaftor licensing and treatment on recorded pancreatic enzyme replacement therapy …

gb, us, bd (code pays fourni par la source)